Cargando…
Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects
BACKGROUND: Data on the safety and efficacy of coronavirus disease 2019 (COVID-19) vaccination in people with a range of primary immunodeficiencies (PIDs) are lacking because these patients were excluded from COVID-19 vaccine trials. This information may help in clinical management of this vulnerabl...
Autores principales: | Pham, Michele N., Murugesan, Kanagavel, Banaei, Niaz, Pinsky, Benjamin A., Tang, Monica, Hoyte, Elisabeth, Lewis, David B., Gernez, Yael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Academy of Allergy, Asthma & Immunology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690218/ https://www.ncbi.nlm.nih.gov/pubmed/34952033 http://dx.doi.org/10.1016/j.jaci.2021.11.022 |
Ejemplares similares
-
Immunogenicity of a third COVID-19 messenger RNA vaccine dose in primary immunodeficiency disorder patients with functional B-cell defects
por: Gernez, Yael, et al.
Publicado: (2022) -
Treatment of chronic or relapsing COVID-19 in immunodeficiency
por: Brown, Li-An K., et al.
Publicado: (2022) -
Interferon-gamma release assay testing to assess COVID-19 vaccination response in a SARS-CoV-2 seronegative patient on rituximab: a case report
por: Ferguson, Jessica, et al.
Publicado: (2021) -
COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience
por: Shields, Adrian M., et al.
Publicado: (2021) -
Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity
por: Hagin, David, et al.
Publicado: (2021)